In vivo response to growth hormone-releasing peptide-6 in adrenocorticotropin-dependent Cushing's syndrome by lung carcinoid tumor is associated with growth hormone secretagogue receptor type 1a mRNA expression

Journal of Endocrinological Investigation

Volumn 30, Issue 4, 2007, Pages 334-340

  Machado, M C ^a   Sa S V ^a   Goldbaum, T S ^a   Catania, M ^a   Campos, V C ^b   Correa Giannella M L C ^a   Giannella Neto, D ^a   Salgado, L R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b University of Sergipe School of Medicine   (Brazil)

Author keywords

ACTH dependent Cushing's syndrome; Carcinoid tumor; GHRP 6; GHS; GHSR 1a

Indexed keywords

ALCOHOL; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; COTRIMOXAZOLE; DESMOPRESSIN; FLUORODEOXYGLUCOSE F 18; GROWTH HORMONE SECRETAGOGUE RECEPTOR; GROWTH HORMONE SECRETAGOGUE RECEPTOR 1A; HISTIDYL DEXTRO TRYPTOPHYLALANYLTRYPTOPHYL DEXTRO PHENYLALANYLLYSINAMIDE; HYDROCORTISONE; KETOCONAZOLE; MESSENGER RNA; OCTREOTIDE; PENTAMIDINE; PENTETREOTIDE IN 111; POTASSIUM; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRONCHUS CARCINOID; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CUSHING DISEASE; DELIRIUM; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOCRINE FUNCTION TEST; GENE OVEREXPRESSION; GENERAL CONDITION DETERIORATION; HALLUCINATION; HORMONE RESPONSE; HUMAN; HUMAN TISSUE; HYPERCORTISOLISM; HYPERTENSION; HYPOKALEMIA; IMAGE ANALYSIS; IN VIVO STUDY; LIVER RESECTION; LUNG CANCER; LUNG INFECTION; LUNG SCINTISCANNING; LYMPHADENECTOMY; MALE; MUSCLE WEAKNESS; NEPHROLITHIASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; OSTEOPOROSIS; PROTEIN EXPRESSION; PSYCHOMOTOR DISORDER; PSYCHOSIS; REAL TIME POLYMERASE CHAIN REACTION; SEPSIS; THORACOTOMY; VERTEBRA FRACTURE;

EID: 34347272222     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03346301     Document Type: Article

References (22)

1. Oldfield EH, Doppman JL, Nieman LK, et al. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome. N Engl J Med 1991, 325: 897-905.
2. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 1998, 19: 647-72.
3. Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F. Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 1999, 84: 440-8.
4. Kaltsas GA, Giannulis MG, Newell-Price JD, et al. A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing's disease and the occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1999, 84: 487-92.
5. Colao A, Faggiano A, Pivonello R, et al.; Study Group of the Italian Endocrinology Society on the Pathophsiology of the Hypothalamic-Pituitary-Adrenal Axis. Inferior petrosal sinus sampling in the differential diagnosis of Cushing's syndrome: results of an Italian multicenter study. Eur J Endocrinol 2001, 144: 499-507.
6. Lefournier V, Martinie M, Vasdev A, et al. Accuracy of bilateral inferior petrosal or cavernous sinuses sampling in predicting the lateralization of Cushing's disease pituitary microadenoma: influence of catheter position and anatomy of venous drainage. J Clin Endocrinol Metab 2003, 88: 196-203.
7. Ghigo E, Arvat E, Ramunni J, et al. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome. J Clin Endocrinol Metab 1997, 82: 2439-44.
8. Arvat E, Giordano R, Ramunni J, et al. Adrenocorticotropin and cortisol hyperresponsiveness to hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenoma. J Clin Endocrinol Metab 1998, 83: 4207-11.
9. Grottoli S, Arvat E, Gauna C, et al. Effects of alprazolam, a benzodiazepine, on the ACTH-, GH- and PRL-releasing activity of hexarelin, a synthetic peptidyl GH secretagogue (GHS), in patients with simple obesity and in patients with Cushing's disease. Pituitary 1999, 2: 197-204.
10. Arvat E, Ramunni J, Giordano R, et al. Effects of the combined administration of hexarelin, a synthetic peptidyl GH secretagogue, and hCRH on ACTH, cortisol and GH secretion in patients with Cushing's disease. J Endocrinol Invest 1999, 22: 23-8.
11. Leal-Cerro A, Torres E, Soto A, et al. Ghrelin is no longer able to stimulate growth hormone secretion in patients with Cushing's syndrome but instead induces exaggerated corticotropin and cortisol responses. Neuroendocrinology 2002, 76: 390-6.
12. Oliveira JH, Vieira JG, Abucham J, Lengyel AM. GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing's disease: comparison with DDAVP. J Endocrinol Invest 2003, 26: 230-5.
13. Arnaldi G, Mancini T, Kola B, et al. Cyclical Cushing's syndrome in a patient with a bronchial neuroendocrine tumor (typical carcinoid) expressing ghrelin and growth hormone secretagogue receptors. J Clin Endocrinol Metab 2003, 88: 5834-40.
14. Pfaffl MW. A new mathematical model for relative quantification in real time RT-PCR. Nucleic Acids Research 2001, 29: e45.
15. Gnanapavan S, Kola B, Bustin SA, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002, 87: 2988.
16. de Keyzer Y, Lenne F, Bertagna X. Widespread transcription of the growth hormone-releasing peptide receptor gene in neuroendocrine human tumors. Eur J Endocrinol 1997, 137: 715-8.
17. Korbonits M, Bustin SA, Kojima M, et al. The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. J Clin Endocrinol Metab 2001, 86: 881-7.
18. Barlier A, Zamora AJ, Grino M, et al. Expression of functional growth hormone secretagogue receptors in human pituitary adenomas: polymerase chain reaction, triple in-situ hybridization and cell culture studies. J Neuroendocrinol 1999, 11: 491-502.
19. Lania A, Ballare E, Corbetta S. Filopanti M, Persani L, Spada A. Growth hormone-releasing hexapeptide (GHRP-6) increases intracellular calcium concentrations in cultured cells from human pituitary adenomas of different types. Eur J Endocrinol 1998, 139: 343-8.
20. Ghe C, Cassoni P, Catapano F, et al. The antiproliferative effect of synthetic peptidyl GH secretagogues in human CALU-1 lung carcinoma cells. Endocrinology 2002, 143: 484-91.
21. Tamura H, Kamegai J, Sugihara H, Kineman RD, Frohman LA, Wakabayashi I. Glucocorticoids regulate pituitary growth hormone secretagogue receptor gene expression. J Neuroendocrinol 2000, 12: 481-5.
22. Petersenn S, Rasch AC, Penshorn M, Beil FU, Schulte HM. Genomic structure and transcriptional regulation of the human growth hormone secretagogue receptor. Endocrinology 2001, 142: 2649-59.